Parathyroid hormone clinical trials are advancing thanks to a breakthrough discovery by researchers at UW-Madison and Harvard Medical School. By modifying the backbone of a synthetic parathyroid hormone, scientists have built a version that resists degradation in laboratory mice, staying active longer and at higher concentrations.
Hormones are signaling molecules that are distributed throughout the body, usually in the blood. Hormones elicit responses from only those cells that carry appropriate receptor molecules. “Receptors have evolved to recognize a very specific signal in a sea of biological fluids that is full of molecular messages,” Gellman said.
The relationship between a receptor and its signaling molecule is often likened to that between a lock and a key.
“We’re excited because we have preserved the ability to activate the receptor” by altering the backbone of the hormone, which holds the essential contact points in place, Gellman said. “While retaining, even enhancing, the signaling ability, we have diminished the peptide’s susceptibility to the biodegradation mechanisms that nature uses to eliminate signals over time.”
Peptides are segments of proteins. Peptide hormones, like the better-known steroid hormones such as estrogen and testosterone, can convey a signal to billions of cells at once, even at tiny concentrations.
Ross Cheloha (Source: University of Wisconsin-Madison)For a study published June in Nature Biotechnology, the researchers altered a highly successful synthetic parathyroid hormone called teriparatide, which is used to combat severe osteoporosis.
But the real excitement of the discovery is the potential impact on a large class of peptide drugs, Gellman said. “A substantial group of receptors, including some involved in diabetes, respond to peptide signals, but peptides are quickly degraded in the body. Our approach seems to suggest a general strategy to retain the ability to target a specific receptor while diminishing the action of degrading enzymes. The key is that the receptor is looking for one shape while the destructive enzyme seeks a different shape.”
Why Parathyroid Hormone Clinical Trials Matter
Parathyroid hormone clinical trials are critical for developing treatments for osteoporosis and diabetes. Current FDA-approved teriparatide treatments have limited dosing windows due to rapid degradation. This new backbone-alteration approach could extend treatment effectiveness and open doors for a broader class of peptide-based drugs targeting similar receptors.
Researchers believe this strategy could be applied to other peptide hormones involved in metabolic diseases, making parathyroid hormone clinical trials a key area of ongoing research in endocrinology and drug development.
To learn more about active clinical trials related to osteoporosis and diabetes, visit ClinicalTrials.gov or explore FOMAT Medical patient active studies.